StocksMedium•4 November 2026•
1 min read
Geron Forecasts Up to $240M in 2026 RYTELO Revenue
Key Facts
1Geron Corporation expects 2026 RYTELO net product revenue to be between $220 million and $240 million.
2The company is initiating the launch of RYTELO in Germany by the end of 2026.
Geron Corporation expects 2026 RYTELO net product revenue to be between $220 million and $240 million. Seeking Alpha reported that the company is initiating the launch of the drug in Germany by the end of 2026 as part of its commercial scaling strategy for imetelstat.
GERN closed at $0.93 on November 3, 2026, having reached a day high of $0.9721 and a low of $0.9232 during that session. These financial projections follow the company's Q3 2026 results and indicate a continued growth trajectory in its biotech operations.